Friday, September 29, 2023

561.316.3330

Biotechnology News Magazine

Novigenix Announces First Closing of Its $20M Series B

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors.

Novigenix‘s Liquid Immuno-Transcriptomic (LITOseek) platform provides previously unknown insights into the molecular pathways associated with onset of cancer and their response to therapy. The company has validated its unique approach in Colorectal Cancer (CRC) screening, and provides new molecular insights and predictive algorithms for patient stratification and monitoring of Immunotherapies.

Dr. Miro Venturi, member of the Board of Directors of Novigenix commented “There is currently a great need in oncology for individualized treatment of patients based on their specific immune subtypes in order to improve outcomes and accelerate development of new therapies. The Novigenix platform has demonstrated a unique differentiated approach that can contribute to more effective patient stratification and therapy monitoring”.

The proceeds will be utilized to fast track the clinical validation of Novigenix´s second generation NGS-based liquid biopsy CRC screening assay, and development of new immunotherapy patient stratification assays. The immuno-transcriptomic cancer-specific profiles obtained from blood draws are combined with multi-modal information such as patient clinical data to predict response to therapy at baseline, and treatment monitoring following therapy.

“We are grateful for the continued support of our long-term investors and are delighted to welcome new investors to our growing shareholder base.” said Dr. Brian Hashemi, Executive Chairman of Novigenix. “This financing round will accelerate expansion of our precision oncology solutions for biopharma applications, and support development of new products on our LITOseek platform to help improve patient outcomes”.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine